Angiotensin II-induced hypertension increases the mutant frequency in rat kidney
Epidemiological studies revealed an increased risk for kidney cancer in hypertensive patients. In many of these patients, the blood pressure regulating renin–angiotensin–aldosterone system (RAAS) is activated. A stimulated RAAS leads to oxidative stress and increases markers of DNA damage, both in vitro and in animal models of hypertension. However, the mutagenic potential of RAAS activation has not been investigated yet. To quantify hypertension-induced mutations, BigBlue®+/− rats, which carry a transgenic lacI gene for mutation analysis, were treated for 20 weeks with a mean dose of 400 µg angiotensin II/kg × day. Angiotensin II-treated animals showed significantly increased blood pressure and impaired kidney function. Urinary excretion of oxidized nucleobases was raised. Additionally, in the renal cortex, oxidative stress, oxidatively generated DNA lesions and DNA strandbreaks were significantly increased. Further, a significant elevation of the mutant frequency in kidney DNA was detected. Sequencing revealed the presence of GC → T:A transversions in the mutated lacI genes of the angiotensin II-treated animals as a result of unrepaired oxidatively modified DNA bases, while no such transversions were found in the mutated lacI genes from control animals. The results demonstrate that the oxidative stress and DNA damage previously observed in kidney cells in vitro and in vivo after angiotensin II treatment indeed is associated with the accumulation of mutations in rat kidneys, providing further evidence for a cancer-initiating potential of elevated angiotensin II concentrations.
KeywordsAngiotensin II Hypertension Mutation frequency BigBlue® 8-oxoG Oxidative stress
The outstanding technical assistance of Kerstin De Mezzo is acknowledged. We thank Iris Schrey and Mandy Knitter for their excellent help during our operations, Stephanie Pohlmann for her help with the perfusion and Annegret Rosner and Wolfgang Manz for the considerate care of our rats.
NS, and BE designed the study, CH and IS carried out experiments and analyzed the data, CH, NS and BE: drafted and revised the manuscript, all authors approved the final version of the manuscript.
This work was supported by the Deutsche Krebshilfe (#110667 to N. S. and #110668 to B. E.).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All animal experiments were performed in accordance with the European Community guidelines for the use of experimental animals and with the German law for the protection of animals (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, permit number 84-02.04.2014.A386). The investigation conformed to the “Guide for the Care and Use of Laboratory Animals” published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Research involving human participant
This article does not contain any studies with human participants performed by any of the authors.
- de Boer JG, Mirsalis JC, Provost GS, Tindall KR, Glickman BW (1996) Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. Environ Mol Mutagen 28(4):418–423. https://doi.org/10.1002/(SICI)1098-2280(1996)28:4%3c418:AID-EM17%3e3.0.CO;2-I CrossRefPubMedGoogle Scholar
- Karanovic D, Grujic-Milanovic J, Miloradovic Z et al (2016) Effects of single and combined losartan and tempol treatments on oxidative stress, kidney structure and function in spontaneously hypertensive rats with early course of proteinuric nephropathy. PLoS One 11(8):e0161706. https://doi.org/10.1371/journal.pone.0161706 CrossRefPubMedPubMedCentralGoogle Scholar
- Osorio H, Coronel I, Arellano A, Franco M, Escalante B, Bautista R (2012) Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract 97(2):276–282. https://doi.org/10.1016/j.diabres.2012.02.022 CrossRefPubMedGoogle Scholar
- Prtenjaca A, Tarnowski HE, Marr AM et al (2014) Relatively high rates of G: C – > A: T transitions at CpG sites were observed in certain epithelial tissues including pancreas and submaxillary gland of adult big blue(R) mice. Environ Mol Mutagen 55(1):51–63. https://doi.org/10.1002/em.21816 CrossRefPubMedGoogle Scholar
- Suzuki T, Itoh T, Hayashi M et al (1996) Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen 28(4):348–353. https://doi.org/10.1002/(SICI)1098-2280(1996)28:4%3c348:AID-EM8%3e3.0.CO;2-7 CrossRefPubMedGoogle Scholar
- Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21(11):1983–1992. https://doi.org/10.1097/01.hjh.0000084751.37215.d2 CrossRefPubMedGoogle Scholar
- Zimnol A, Amann K, Mandel P, Hartmann C, Schupp N (2017) Angiotensin II type 1a receptor-deficient mice develop angiotensin II-induced oxidative stress and DNA damage without blood pressure increase. Am J Physiol Renal Physiol. https://doi.org/10.1152/ajprenal.00183.2017 CrossRefPubMedGoogle Scholar